证券代码：603233 证券简称：大参林 公告编号：2025-045 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 374 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 868,815,290 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 76.7419 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，经过半数董事推举，由董事柯国强主持本次股 东大会。会议采取现场投票及网络投票方式召开并表决。会议的召集和召开符合 《公司法》《上市公司股东大会规则》和《公司章程》等有关规定。 (一) 股东大会召开的时间：2025 年 6 月 25 日 (二) 股东大会召开的地点：广州市荔湾区龙溪大道 410 号大参林集团综合楼 4 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先 ...

关于大参林医药集团股份有限公司 2025 年第一次临时股东大会的法律意见书 北京市金杜（广州）律师事务所 致：大参林医药集团股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受大参林医药集团股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境 内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中 国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件 和现行有效的公司章程有关规定，指派律师出席了公司于 2025 年 6 月 25 日召开 的 2025 年第一次临时股东大会（以下简称本次股东大会），并就本次股东大会相 关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1 1． 经公司 2024 年年度股东大会审议通过的《大参林医药集团股份有限公司 章程》（以下简称《公司章程》）； 2． 公司 2025 年 6 月 10 日刊登于《中国证券报》《证 ...

证券代码：603233 证券简称：大参林 公告编号：2025-044 大参林医药集团股份有限公司 关于公司控股股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担连带责任。 重要内容提示： 于其他保障用途。 3、股东累计质押股份情况 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： 单位：股 股东 名称 是否 为控 股股 东 本次质押股 数（股） 是否为限售 股 是否 补充 质押 质押起始 日 质押到期 日 质权人 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 质押融 资资金 用途 柯康 保 是 15,000,000 否 否 2025 年 6 月 23 日 2026 年 6 月 24 日 兴业国际 信托有限 公司 8.42 1.32 个人用 途 合计 - 15,000,000 - - - - - 8.42 1.32 - 大参林医药集团股份有限公司（以下简称"公司"或"本公司"）控股股东 之一的柯康保先生持有公司无限售条件流通股178,192,742股，占公司总股 本的15.65%。 截至公告披露日 ...

Group 1 - The A-share market showed mixed performance with the national free cash flow index slightly declining by approximately 0.15%, while component stocks experienced varied movements, with Jinjiang Shipping leading gains and Dazhenglin facing losses [1] - The low-fee free cash flow ETF (159201) actively traded in line with the index adjustment, currently holding a scale of 3.698 billion yuan, leading among similar products [1] - CITIC Securities indicated that the previously strong-performing Hong Kong new consumption and innovative pharmaceutical sectors have recently undergone significant adjustments, impacting related A-share sectors, with liquidity and risk appetite in Hong Kong facing ongoing challenges [1] Group 2 - The free cash flow ETF (159201) closely tracks the national free cash flow index and has demonstrated strong long-term performance [1] - The free cash flow stock selection strategy offers substantial allocation value, with a portfolio structure that significantly differs from traditional dividend strategies, showing stronger aggressiveness in value markets, making it an excellent complement to defensive strategies [1]

Core Viewpoint - The 15th Yulin Traditional Chinese Medicine Expo is being held in Yulin, Guangxi, attracting businesses to explore opportunities in the "Southern Medicine Capital" [1][3]. Group 1: Event Overview - The expo features a professional exhibition area of 70,000 square meters, showcasing renowned pharmaceutical companies, quality medicinal materials, advanced medical devices, and health products from across China [1]. - Concurrently, the 2025 Yulin Traditional Chinese Medicine Health Industry Investment Promotion Conference took place, resulting in the signing of 12 projects, including the deep processing of agarwood and an online trading platform for medicinal materials [1][3]. Group 2: Industry Significance - Yulin is a major production area for medicinal materials in Guangxi, hosting China's third-largest professional market for traditional Chinese medicine, with over 3,000 varieties and an annual transaction volume of 12 billion RMB [1]. - The city is recognized as "Southern Fragrance Capital," featuring the largest and most diverse international spice market in China [1]. Group 3: Future Development - Yulin is actively building an open platform connecting ASEAN and the global market, aiming to create a national-level health industry hub that integrates planting, processing, research, trading, exhibitions, and wellness [5]. - The Yulin Traditional Chinese Medicine Health Industry Park covers an area of 24 square kilometers and has attracted 98 enterprises, including well-known pharmaceutical companies [3].

Core Viewpoint - The company is responding to an inquiry regarding its 2024 annual report, addressing concerns about revenue growth slowdown, net profit decline, and the stability of gross profit margins amidst industry challenges and regulatory changes [1][2]. Group 1: Financial Performance - The company's revenue for 2022, 2023, and 2024 was 20.176 billion, 22.437 billion, and 22.358 billion RMB, with year-on-year growth rates of 28.54%, 11.21%, and -0.36% respectively [2]. - The net profit attributable to shareholders for the same years was 0.785 billion, 0.929 billion, and 0.519 billion RMB, with year-on-year changes of 17.29%, 18.35%, and -44.13% respectively [2]. - The overall gross profit margin has shown stable growth, with the gross profit margin for 2024 at 41.4% compared to 39.6% in 2023 and 40.4% in 2022 [5]. Group 2: Industry Challenges - The pharmaceutical retail industry is experiencing revenue stagnation and profit pressure due to ongoing medical reforms, stricter insurance regulations, and increased market competition [3][4]. - The number of retail pharmacies in China reached 675,000 by the end of 2024, reflecting a growth of 1.21% from the previous year, indicating intensified competition in the market [4]. Group 3: Strategic Adjustments - In response to market conditions, the company has increased the number of self-built and franchised stores to enhance market share, with the total number of stores reaching 14,684 in 2024, up from 10,268 in 2022 [4]. - The company is shifting its product strategy towards traditional Chinese and Western medicines, with sales of these products accounting for 79.1% of total revenue in 2024 [5]. - The company has implemented measures to optimize its supply chain and improve operational efficiency, including a focus on private label products, which generated sales of 3.54 billion RMB in 2024, accounting for 22% of total sales [5][6]. Group 4: Goodwill and Asset Management - The company has a significant goodwill balance of 5.756 billion RMB as of the end of 2024, representing 27.35% of total assets, necessitating careful management and impairment testing of goodwill [2][3]. - The company conducts goodwill impairment tests based on asset groups defined by operational units, ensuring compliance with accounting standards [6][8].

Core Viewpoint - The company, Lao Bai Xing Pharmacy, has experienced significant fluctuations in performance over recent years, with stable growth in gross profit margin despite a decline in net profit and revenue growth slowdown. The company faces challenges from industry competition and regulatory changes in the healthcare sector [2][4]. Financial Performance - Revenue for the years 2022 to 2024 was reported as follows: 20.176 billion, 22.437 billion, and 22.358 billion RMB, with year-on-year changes of 28.54%, 11.21%, and -0.36% respectively. Net profit for the same period was 0.785 billion, 0.929 billion, and 0.519 billion RMB, with changes of 17.29%, 18.35%, and -44.13% respectively [2]. - The overall gross profit margin for the years was 31.88%, 32.56%, and 32.50% [2]. Business Strategy and Market Conditions - The company has been increasing the number of self-built and franchised stores to enhance market share, with total store numbers reaching 15,277 in 2024, up from 13,574 in 2023 and 10,783 in 2022 [6]. - The company is also focusing on online sales channels, with public domain B2C and O2O sales accounting for 10.3% of total revenue in 2024, up from 9.3% in 2023 and 6.6% in 2022 [6]. - The company has adjusted its product strategy to focus more on traditional Chinese and Western medicine, with sales of traditional Chinese and Western medicine accounting for 77.5% of total revenue in 2024 [7]. Industry Challenges - The retail pharmacy market is facing a slowdown in growth, with the total retail pharmacy market sales reaching 528.2 billion RMB in 2024, a year-on-year decline of 2.2% [5]. - The industry is experiencing increased competition, with a total of 675,000 pharmacies in China as of the end of 2024, serving an average of 2,000 people per pharmacy, compared to 5,000 in the United States [5]. Goodwill and Impairment - As of the end of 2024, the company's goodwill balance was 5.756 billion RMB, accounting for 27.35% of total assets. The company recognized a goodwill impairment provision of approximately 0.108 billion RMB for the year [2]. - The company classifies its goodwill based on regional divisions, and the impairment testing process is conducted in accordance with accounting standards [8][10]. Operational Efficiency - The company has implemented measures to improve operational efficiency, including restructuring product selection strategies, enhancing digital product introductions, and optimizing supply chain costs [7]. - The company’s gross profit margin has shown a continuous increase, with a comprehensive gross profit margin of 36.4% in 2024, up from 35.7% in 2023 [7].

Core Viewpoint - The company is preparing for its upcoming shareholder meeting scheduled for June 25, 2025, focusing on the election of a new non-independent director and ensuring compliance with relevant laws and regulations [2][3][5]. Meeting Details - The meeting will be held at the company's headquarters in Guangzhou, with both on-site and online voting options available for shareholders [2][3]. - The meeting will commence at 10:30 AM, with specific time slots allocated for online voting [2]. Agenda and Procedures - The agenda includes signing in, announcing the number of shareholders present, selecting vote counters, and discussing various proposals [2][3][4]. - Shareholders will have the opportunity to speak and vote on the proposals, with specific rules governing the speaking time and number of times a shareholder can speak [3][5]. Proposal for Director Election - A key proposal involves the election of Mr. Ke Tuoki as a non-independent director, nominated by the controlling shareholder Mr. Ke Yunfeng [5][6]. - Mr. Ke Tuoki has no current shareholding in the company and is related to Mr. Ke Yunfeng as his son, which aligns with the company's nomination regulations [5][6]. Qualifications of the Nominee - The nomination committee has reviewed Mr. Ke Tuoki's qualifications and confirmed that he meets the necessary criteria to serve as a director [6]. - There are no legal restrictions preventing him from holding the position, and he is not listed as a market disqualified individual by the China Securities Regulatory Commission [6].

2025 年第一次临时股东大会会议材料 大参林医药集团股份有限公司 2025 年第一次临时股东大会 会议材料 二○二五年六月 2025 年第一次临时股东大会会议材料 目 录 | 2025 | 年第一次临时股东大会会议议程 | 1 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议须知 | 3 | | 2025 | 年第一次临时股东大会会议议案 | 4 | | | 议案一：关于选举第四届董事会非独立董事的议案 | 4 | 2025 年第一次临时股东大会会议材料 大参林医药集团股份有限公司 2025 年第一次临时股东大会会议议程 会议表决方式：现场投票与网络投票相结合的方式 会议时间：2025 年 6 月 25 日上午 10 点 30 分 网络投票：2025 年 6 月 25 日 网络投票起止时间：采用上海证券交易所网络投票系统，通过交易系统投票 平台的投票时间为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 会议地点：广东省广州市荔湾区龙溪大道 41 ...

Core Viewpoint - The 2024 China Chain Top 100 report indicates a mixed performance across various retail sectors, with significant challenges for comprehensive retail while supermarkets and specialty stores show growth potential [1][3][11]. Group 1: Overall Performance - The overall sales scale of the top 100 chain enterprises in China for 2024 is 2.13 trillion yuan, with a total of 257,200 stores, representing a growth of 4.9% and 13.5% respectively compared to 2023 [1]. - Notable companies such as Walmart (China), Suining Yigou, and Hema maintain their leading positions, with Walmart (China) achieving sales of 158.845 billion yuan [2]. Group 2: Comprehensive Retail Sector - The comprehensive retail sector faces significant growth pressure, with only 19 out of 46 companies showing year-on-year sales growth, and just 9 achieving both sales and store number growth [4]. - Companies like Suning Yigou and CR Vanguard experienced substantial declines in sales, with decreases of 14.1% and 23.1% respectively, alongside reductions in store numbers [5]. - The challenges faced by comprehensive retail are not new, as evidenced by declines in 2023, indicating a trend of stagnation due to rising costs and increased online sales penetration [5]. Group 3: Supermarkets and Convenience Stores - The supermarket sector shows signs of improvement, with 12 out of 23 companies reporting sales growth, including Hema and Jiajiayue, which achieved significant increases in both sales and store numbers [7]. - Hema's sales exceeded 75 billion yuan, growing by 27.1%, while Pang Donglai reported a remarkable 58.5% increase in sales [7][8]. - Convenience stores continue to grow, but the growth rate has slowed significantly for major players like Meiyijia and 7-Eleven, indicating a potential saturation in the market [9][10]. Group 4: Specialty Stores - Specialty stores are emerging as a new growth driver, with strong performance across various segments such as pharmaceuticals and beauty products, showing double-digit growth in both sales and store numbers [11]. - Companies like Dazhenglin and Kidswant are expanding rapidly, with Dazhenglin's store count increasing by 17.6% [12]. - The snack industry is witnessing the rise of new discount brands, with Hunan Mingming Hen Mang entering the top 10 with a staggering 132.7% sales growth [13]. Group 5: Future Trends - The competition among chain enterprises will increasingly depend on user engagement, service experience, product precision, and technological support [13]. - As the retail market evolves, specialty stores must enhance their competitiveness to address pressures from other retail formats and e-commerce platforms [13].